Skip Navigation

European Journal of Heart Failure 2006 8(7):764-766; doi:10.1016/j.ejheart.2006.10.001
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (14)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cleland, J. G.F.
Right arrow Articles by Clark, A. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cleland, J. G.F.
Right arrow Articles by Clark, A. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society of Cardiology

Clinical trials update from the Heart Failure Society of America meeting: FIX-CHF-4, selective cardiac myosin activator and OPT-CHF

John G.F. Cleland*, Alison P. Coletta and Andrew L. Clark

Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, Kingston-upon-Hull, HU15 5JQ, UK

* Corresponding author. Tel.: +44 1482 624086; fax: +44 1482 624085. E-mail address: a.p.coletta{at}hull.ac.uk (J.G.P.Cleland).


  Abstract

This article provides information and a commentary on trials relevant to the pathophysiology, prevention and treatment of heart failure, presented at the Heart Failure Society of America meeting held in Seattle in September 2006. All reports should be considered as preliminary data, as analyses may change in the final publication.

Devices designed to improve cardiac contractility may have improved exercise tolerance and quality of life in the FIX-CHF-4 study; however, uncertainties in trial interpretation exist. The results of a study reporting the first administration of the selective myosin activator CK-1827452 to human volunteers, support the initiation of clinical trials in heart failure patients. In OPT-CHF, oxypurinol failed to show benefit compared to placebo for the treatment of heart failure, although a retrospective subgroup analysis suggests that it may be beneficial in patients with elevated serum uric acid levels.

Key Words: FIX-CHF-4 • Selective cardiac myosin activator • OPT-CHF

Received October 2, 2006; Accepted October 2, 2006


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Circ Heart FailHome page
E. Krishnan
Hyperuricemia and Incident Heart Failure
Circ Heart Fail, November 1, 2009; 2(6): 556 - 562.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
S. Sadayappan, J. Gulick, R. Klevitsky, J. N. Lorenz, M. Sargent, J. D. Molkentin, and J. Robbins
Cardiac Myosin Binding Protein-C Phosphorylation in a {beta}-Myosin Heavy Chain Background
Circulation, March 10, 2009; 119(9): 1253 - 1262.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
A. P. Coletta, J. G.F. Cleland, D. Cullington, and A. L. Clark
Clinical trials update from Heart Rhythm 2008 and Heart Failure 2008: ATHENA, URGENT, INH study, HEART and CK-1827452
Eur J Heart Fail, September 1, 2008; 10(9): 917 - 920.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
A. L. Moens, E. Takimoto, C. G. Tocchetti, K. Chakir, D. Bedja, G. Cormaci, E. A. Ketner, M. Majmudar, K. Gabrielson, M. K. Halushka, et al.
Reversal of Cardiac Hypertrophy and Fibrosis From Pressure Overload by Tetrahydrobiopterin: Efficacy of Recoupling Nitric Oxide Synthase as a Therapeutic Strategy
Circulation, May 20, 2008; 117(20): 2626 - 2636.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
L. De Luca, A. Mebazaa, G. Filippatos, J. T. Parissis, M. Bohm, A. A. Voors, M. Nieminen, F. Zannad, A. Rhodes, A. El-Banayosy, et al.
Overview of emerging pharmacologic agents for acute heart failure syndromes
Eur J Heart Fail, February 1, 2008; 10(2): 201 - 213.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.